


**RAN-Formular (Rapid-Alert-Notification) zur Mitteilung über den RAS-Verteiler**

**DRINGEND - BITTE SOFORT AUSLIEFERN! IMPORTANT - DELIVER IMMEDIATELY**

| <b>Rapid Alert Notification of a Medicinal Product Falsification</b>   |  |
|--|--|
| <input type="checkbox"/> <b>ASSUMED</b> <input type="checkbox"/> <b>REASONABLY SUSPECTED</b> <input checked="" type="checkbox"/> <b>VERIFIED</b> |  |
| Landesverwaltungsamt<br>Referat Gesundheitswesen, Pharmazie<br>Referatsbereich Pharmazie<br>Ernst-Kamieth-Straße 2<br>06112 Halle (Saale)        |  |
| 1. To/Empfänger:   | FAX  |
| <input checked="" type="checkbox"/> Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM)  | 0228-207-4636  |
| <input type="checkbox"/> Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL)  | 030-18444-30409  |
| <input type="checkbox"/> Paul-Ehrlich-Institut/Bundesamt für Sera und Impfstoffe (PEI)   | 06103-77-1263  |
| <input checked="" type="checkbox"/> <Oberste Landesbehörde>  | 0391-567-6912  |
| 2. Classification (not mandatory)<br>---   | 3. Falsification:<br>Theft   |
| 4. Product:<br>esketamine hydrochloride solution for injection   | 5. Marketing Authorisation Number: *<br>1-22524<br>For use in humans                                       |
| 6. Brand/Trade Name:<br>Ketanest S 5 mg/ml   | 7. INN or Generic Name:<br>esketamine hydrochloride  |
| 8. Dosage Form:<br>solution for injection  | 9. Strength:<br>5 mg/ml  |
| 10. Batch number (and bulk, if different):<br>a) X63047<br>b) AW0433   | 11. Expiry Date:<br>a) 04/2021<br>b) 07/2021   |
| 12. Pack size and Presentation:<br>10 x 5 ml ampoules, austrian presentation   | 13. Date Manufactured: *<br>a) 04/2018<br>b) 07/2018   |
| 14. Marketing Authorisation Holder: Pfizer Corporation Austria Ges.m.b.H., Vienna, Austria   |  |
| 15. Manufacturer†:<br>Pfizer Manufacturing Belgium NV, Puurs,<br>Belgium<br><br>Contact Person: ---<br>Telephone: ---                            | 16. Recalling Firm<br> |
| 17. Rapid Alert Notification Reference Number: <b>DE_</b>  |  |

|  |  |             |
|--|--|-------------|
| 18. Details: The manufacturer MPA Pharma GmbH (contract manufacturer of the parallel importer EMRAmed Arzneimittel GmbH in Germany) informed the responsible authority, that eleven packages of Ketanest S 5 mg/ml (two packages of batch no. X63047, not marked with serial numbers; nine packages of batch no. AW0433, marked with serial numbers) have been stolen from the warehouse at the production site in Osterburg (Germany). The theft was detected on 13 <sup>th</sup> August 2020. MPA Pharma GmbH submitted charge against unknown at the police. The serial numbers of batch no. AW0433 have been registered as stolen by MPA Pharma GmbH at the hub. |  |             |
| 19. Information on distribution including exports (e. g. type of customer, e.g. hospitals):*<br>Not applicable   |  |             |
| 20. Action taken by Issuing Authority: FOR YOUR INFORMATION  |  |             |
| 21. Proposed Action: ---   |  |             |
| 22. From (Issuing Authority):<br><br>Landesverwaltungsamt<br>Referat Gesundheitswesen, Pharmazie<br>Referatsbereich Pharmazie<br>Ernst-Kamieth-Straße 2<br>06112 Halle (Saale)   | 23. Contact Person:<br><br>Kathrin Hoffmann<br>Telephone: +49345 514 1286<br>Fax: +49345 514 1291<br>mail to: pharmazie@lvwa.sachsen-anhalt.de |             |
| 24. Signed:   | 25. Date: 02.09.2020   | 26. Time: * |

\* Information not required, when notified from outside EU.

† The holder of an authorisation referred to under Article 40 of Directive 2001/83/EC or Article 44 of Directive 2001/82/EC and the holder of the authorisation on behalf of whom the Qualified Person has certified the batch for release in accordance with Article 51 of Directive 2001/83/EC or Article 55 of Directive 2001/82/EC if different.

*This is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us by telephone immediately and return it to us at the above address by mail. Thank you.*